Mirati Therapeutics describes new GTPase KRAS and mutant inhibitors for cancer
Jan. 3, 2024
Mirati Therapeutics Inc. has identified compounds acting as GTPase KRAS and/or GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.